BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24913195)

  • 1. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?
    Bain BJ; Ahmad S
    Br J Haematol; 2014 Sep; 166(6):809-17. PubMed ID: 24913195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
    Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
    Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
    Reiter A; Walz C; Watmore A; Schoch C; Blau I; Schlegelberger B; Berger U; Telford N; Aruliah S; Yin JA; Vanstraelen D; Barker HF; Taylor PC; O'Driscoll A; Benedetti F; Rudolph C; Kolb HJ; Hochhaus A; Hehlmann R; Chase A; Cross NC
    Cancer Res; 2005 Apr; 65(7):2662-7. PubMed ID: 15805263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.
    Tang G; Sydney Sir Philip JK; Weinberg O; Tam W; Sadigh S; Lake JI; Margolskee EM; Rogers HJ; Miranda RN; Bueso-Ramos C C; Hsi ED; Orazi A; Hasserjian RP; Arber DA; Bagg A; Wang SA
    Mod Pathol; 2019 Apr; 32(4):490-498. PubMed ID: 30401948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.
    Bousquet M; Quelen C; De Mas V; Duchayne E; Roquefeuil B; Delsol G; Laurent G; Dastugue N; Brousset P
    Oncogene; 2005 Nov; 24(48):7248-52. PubMed ID: 16091753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.
    Griesinger F; Hennig H; Hillmer F; Podleschny M; Steffens R; Pies A; Wörmann B; Haase D; Bohlander SK
    Genes Chromosomes Cancer; 2005 Nov; 44(3):329-33. PubMed ID: 16001431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature.
    Kantarcioglu B; Kaygusuz-Atagunduz I; Uzay A; Toptas T; Tuglular TF; Bayik M
    Int J Hematol; 2015 Sep; 102(3):383-7. PubMed ID: 25833723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5.
    Ehrentraut S; Nagel S; Scherr ME; Schneider B; Quentmeier H; Geffers R; Kaufmann M; Meyer C; Prochorec-Sobieszek M; Ketterling RP; Knudson RA; Feldman AL; Kadin ME; Drexler HG; MacLeod RA
    PLoS One; 2013; 8(1):e53767. PubMed ID: 23372669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated genomic analysis using chromosomal microarray, fluorescence in situ hybridization and mate pair analyses: Characterization of a cryptic t(9;22)(p24.1;q11.2)/BCR-JAK2 in myeloid/lymphoid neoplasm with eosinophilia.
    Snider JS; Znoyko I; Lindsey KG; Morse J; Baughn LB; Hoppman NL; Pitel BA; Pearce KE; Schandl CA; Wolff DJ
    Cancer Genet; 2020 Aug; 246-247():44-47. PubMed ID: 32827877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.
    Peeters P; Raynaud SD; Cools J; Wlodarska I; Grosgeorge J; Philip P; Monpoux F; Van Rompaey L; Baens M; Van den Berghe H; Marynen P
    Blood; 1997 Oct; 90(7):2535-40. PubMed ID: 9326218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Ph-negative chronic myeloid leukemia with a complex BCR/ABL rearrangement and a t(6;9)(p21;q34.1).
    Todorić-Zivanović B; Marisavljević D; Surace C; Cemerikić V; Marković O; Krtolica K; Tatomirović Z; Cikota B; Magić Z; Rocchi M
    Cancer Genet Cytogenet; 2006 Apr; 166(2):180-5. PubMed ID: 16631477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia.
    La Starza R; Trubia M; Testoni N; Ottaviani E; Belloni E; Crescenzi B; Martelli M; Flandrin G; Pelicci PG; Mecucci C
    Haematologica; 2002 Aug; 87(8):789-94. PubMed ID: 12161353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukaemia cutis in atypical chronic myeloid leukaemia with a t(9;22) (p24;q11.2) leading to BCR-JAK2 fusion.
    Lane SW; Fairbairn DJ; McCarthy C; Nandini A; Perry-Keene J; Kennedy GA
    Br J Haematol; 2008 Aug; 142(4):503. PubMed ID: 18537978
    [No Abstract]   [Full Text] [Related]  

  • 14. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia.
    Cirmena G; Aliano S; Fugazza G; Bruzzone R; Garuti A; Bocciardi R; Bacigalupo A; Ravazzolo R; Ballestrero A; Sessarego M
    Cancer Genet Cytogenet; 2008 Jun; 183(2):105-8. PubMed ID: 18503828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication of MAPK1/MAPK3 signalling pathway in t(8;9)(p22;24)/PCM1-JAK2 myelodysplastic/myeloproliferative neoplasms.
    Masselli E; Mecucci C; Gobbi G; Carubbi C; Pierini V; Sammarelli G; Bonomini S; Prezioso L; Rossetti E; Caramatti C; Aversa F; Vitale M
    Br J Haematol; 2013 Aug; 162(4):563-6. PubMed ID: 23701125
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target?
    Prochorec-Sobieszek M; Nasiłowska-Adamska B; Borg K; Kopeć I; Kos-Zakrzewska K; Juszczyński P; Warzocha K
    Leuk Lymphoma; 2012 Sep; 53(9):1824-7. PubMed ID: 22288769
    [No Abstract]   [Full Text] [Related]  

  • 17. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.
    He R; Greipp PT; Rangan A; Mai M; Chen D; Reichard KK; Nelsen LL; Pardanani A; Hanson CA; Viswanatha DS
    Cancer Genet; 2016 May; 209(5):223-8. PubMed ID: 27134074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
    Schwaab J; Knut M; Haferlach C; Metzgeroth G; Horny HP; Chase A; Tapper W; Score J; Waghorn K; Naumann N; Jawhar M; Fabarius A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2015 Feb; 94(2):233-8. PubMed ID: 25260694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.
    Murati A; Gelsi-Boyer V; Adélaïde J; Perot C; Talmant P; Giraudier S; Lodé L; Letessier A; Delaval B; Brunel V; Imbert M; Garand R; Xerri L; Birnbaum D; Mozziconacci MJ; Chaffanet M
    Leukemia; 2005 Sep; 19(9):1692-6. PubMed ID: 16034466
    [No Abstract]   [Full Text] [Related]  

  • 20. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma.
    Van Roosbroeck K; Cox L; Tousseyn T; Lahortiga I; Gielen O; Cauwelier B; De Paepe P; Verhoef G; Marynen P; Vandenberghe P; De Wolf-Peeters C; Cools J; Wlodarska I
    Blood; 2011 Apr; 117(15):4056-64. PubMed ID: 21325169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.